Hydroxychloroquine in Coronavirus Disease 2019 Patients: What Still Needs to Be Known About the Kinetics

Guillaume Martin-Blondel (1) , Stéphanie Ruiz (2) , Marlene Murris (3) , Stanilas Faguer (4) , Véronigue Duhalde , Frédéric Eyvrard , Jacques Izopet (5) , Jean-Michel Mansuy (5) , Yves Rolland (6) , Karen Delavigne (7) , Rosine Guimbaud , Grégory Pugnet , Jean-Marie Conil (2) , Bernard Georges (2) , Pierre Delobel (1) , Vincent Minville (2) , Stein Silva Sifontes (2) , Didier Concordet (8, 9) , Peggy Gandia (10)

1 CPTP - Centre de Physiopathologie Toulouse Purpan
2 Pôle Anesthésie Réanimation [CHU de Toulouse]
3 Service de pneumologie [Toulouse]
4 Département de Néphrologie et Transplantation d'organes [CHU Toulouse]
5 Laboratoire Virologie [CHU Toulouse]
6 Gérontopôle
7 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
8 InTheRes - Innovations Thérapeutiques et Résistances
9 ENVT - Ecole Nationale Vétérinaire de Toulouse
10 Laboratoire Pharmacocinétique et de Toxicologie [CHU Toulouse]

Different dosage regimens of hydroxychloroquine are used to manage coronavirus disease 2019 (COVID-19) patients, without information on the pharmacokinetics in this population. Blood samples (n = 101) were collected from 57 COVID-19 patients for 7 days, and concentrations were compared with simulated kinetic profiles. Hydroxychloroquine exposure is low and cannot be predicted by other populations.

Mots clés: COVID-19; hydroxychloroquine; drug monitoring; population pharmacokinetic modeling; dosage regimens; kinetics; pharmacokinetics

Domaines: Maladies infectieuses

Guillaume Martin-Blondel, Stéphanie Ruiz, Marlene Murris, Stanilas Faguer, Véronigue Duhalde, et al.. Hydroxychloroquine in Coronavirus Disease 2019 Patients: What Still Needs to Be Known About the Kinetics. Clinical Infectious Diseases, 2020, 71 (11), pp.2962-2964. ⟨10.1093/cid/ciaa558⟩. ⟨hal-03167732⟩